LumiraDx Limited

Hello, and welcome to the Lumera DX First Quarter 2022 Earnings Call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your touch-tone phone. To withdraw your question, please press star then two. I would now like to turn the conference over to Colleen McMillan, Vice President of Communications. Please go ahead, ma'am.

Hello, everyone. We'd like to welcome you to today's call to discuss Lumiere DX's first quarter 2022 financial results issued earlier today. With us are Lumiere DX's chairman and CEO, Ron Wanziger, chief financial officer, Dorian LeBlanc, and chief product officer, Pusha Patek. The press release announcing our financial results is posted on the investor relations section of the company's website at lumieredx.com. Before we begin, I would like to caution listeners that the statements we make today, other than historical facts, are forward-looking statements made pursuant to the safe harbor provisions of the Private Security Litigation Reform Act of 1995. Please be aware that all such forward-looking statements involve risk and uncertainties, such as those detailed in our annual report on Form 20F for the year ended December 31, 2021, which was filed with the SEC on April 13th, 2022, and other filings that we make with the SEC. Any forward-looking statements that we make must be considered in light of these factors. Actual results may vary materially. Also, during the course of today's call, we may refer to certain non-IFRS financial measures. Non-IFRS financial measures should not be considered in isolation from or as a substitute for financial information presented in compliance with IFRS. There is a reconciliation schedule showing the IFRS versus non-IFRS results currently available in our press release issued earlier today, which can be found on our website. I will now turn the call over to Ron Zwanziger for opening remarks. We will then provide financial and business updates before answering questions. Ron?

Thanks, Colleen, and thank you all for joining our call today. Our company had a strong start to the year. We've continued to innovate on our platform to deliver the fastest test results on the market with lab-comparable performance. As anticipated, we ended the quarter with approximately 25,000 instruments shipped across 100 countries. Customer receptivity continues to drive market adoption and use cases for our platform in health systems and community-based settings. We've also gained momentum with our R&D pipeline and product launches of assays for common health conditions. We believe that this progress will enable us to drive strong growth of non-COVID revenues in the medium term and deliver on our vision of transforming the 15 billion addressable market for point of care diagnostics. Going to our financial results, we generated 126 million in revenues for the first quarter. The performance was driven by a strong demand for rapid antigen COVID testing on our platform, as well as molecular lab testing by Fast Lab Solutions customers. This was especially the case in January at the height of the Omicron variant surge in cases. We're making progress in our pipeline of the 30-plus diagnostic tests for common health conditions, including infectious diseases, cardiovascular disease, diabetes, and coagulation disorders. On the product delivery side, we've gave momentum with our R&D portfolio with new product launches expected, such as hemoglobin A1C, planned starting this summer, as well as additional claims with Mark and markets for CRP, D-dimer, COVID Ultra, and our COVID and flu combo. I would like to take a moment to highlight our new Ultra test strip, for which we plan to achieve C mark for shortly and some mid for the FDA EUA in this quarter, and which will further reduce our market leading turnaround time to five minutes to test results with high sensitivity. Speed and accuracy of test results are core to Lumira DX's transformative potential and competitive advantage in point of care diagnostics. Five minutes compares to 15 to 30 minutes for most other point of care diagnostic tests on the market and hours or even days for high sensitivity lab testing. The time saved in diagnosis could mean life saved for acute care patients and result in significant increase in throughput for hospitals, pharmacy chains, and other locations with high testing volumes. On the commercial side, we've had the opportunity to work more closely with customers to understand their overall platform experience and enhance its potential impact. That includes positive feedback on recently launched tests, such as D-Diamond CRP, in addition to insights on how our platform can help our customers improve clinical pathways now and additional features and products that will help them expand point of care applications in the future. Our customer success stories should give you a sense of the growing validation by healthcare providers and resulting market adoption and use cases for our platform. Let me share three such examples with you. One, such example on the flexibility of our platform is in the Liverpool Heart and Chest Hospital. The customer is using our CRP test to support patients who have a diagnosis of COPD, bronchiectasis, and or pneumonia as part of their community care. The respiratory team visits patients in the community, and they're able to measure CRP at the point of care when needed within four minutes. The platform, the Lumira DX platform portability has been ideal for this near patient use case and has the connectivity features that allow transfer of patient results to their health records. On our last call, we discussed the experience of the Gloucestershire England Health System using our platform to triage patients in community care settings before they arrive at the hospital and to support a number of tests, including COVID antigen, DDIR, and CRP to streamline resources. Recently, they have tripled their installed base of Lumira DF platform and are planning to implement INR and hypoglomic A1C tests later this year. Finally, for those of you who have not already watched Bill Gates' recent TED talk at TED 2022 in April, LumiraDx platform featured in his talk on preventing the next pandemic. As you know, the foundation has partnered with LumiraDx to distribute 5,000 platforms in African countries to vastly expand testing and transform patient diagnosis and treatment at the point of care. We've now made our platform available in 49 countries in Africa in a variety of care settings, such as field clinics, airports, primary health facilities, occupational health settings, and walk-through clinics. In addition to our current testing menu, we expect that assays in our R&D pipeline for TB, diabetes, HIV, AIDS, and other health conditions will have a meaningful impact on global health. things over to Dorian to go deeper into our financial performance. Dorian?